原发性胆汁性肝硬化药物治疗进展

doi:10.3969/j.issn.1672-5069.2015.02.032

摘要/Abstract

摘要： 治疗原发性胆汁性肝硬化（PBC）的药物主要包括加速胆汁排泄、免疫调节、抗纤维化以及对症治疗等。熊去氧胆酸是目前唯一被批准治疗PBC的药物，对大多数患者有较好的疗效，但仍有部分患者不应答。另外，贝特类、6-乙基鹅去氧胆酸、布地奈德等用于PBC的治疗也显示有很好的前景，这些研究结果为PBC的治疗提供了新选择。

关键词: 原发性胆汁性肝硬化, 药物治疗, 进展

Abstract: Primary biliary cirrhosis （PBC） is one of the autoimmune liver diseases. Ursodeoxycholic acid（UDCA） is the only therapeutic drug approved by FDA. Most patients have a good response to UDCA. Many research on treatment of PBC for the use of fibrates，6- ethyl chenodeoxycholic acid，and budesonide，shows promising results.

Key words: Primary biliary cirrhosis, Ursodeoxycholic acid, Budesonide

李萍英，陆伦根. 原发性胆汁性肝硬化药物治疗进展[J]. 实用肝脏病杂志, 2015, 18(4): 441-444.

Li Pingying，Lu Lungen. Advances in pharmacotherapy of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 441-444.

参考文献

[1] Selmi C，Bowlus CL，Gershwin ME，et al. Primary biliary cirrhosis. Lancet，2011，377：1600-1609．
[2] Boberg KM，Wisloff T，Kjollesdal KS，et al. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther，2013，38（7）：794-803.
[3] Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases：an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol， 2012，36（Suppl 1）：S3-S12.
[4] Leuschner U，Manns MP，Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis：effects on progression and prognosis. Z Gastroenterol，2005，43（9）：1051-1059.
[5] Rautiainen H，Karkkainen P，Karvonen AL，et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis：a three-year randomized trial. Hepatology，2005，41（4）：747-752.
[6] Corpechot C，Abenavoli L，Rabahi N，et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology，2008，48：871-877.
[7] Fiorucci S，Cipriani S，Mencarelli A，et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders： focus on 6-ethyl-CDCA. Mini Rev Med Chem，2011，11（9）：753-762.
[8] Beuers U，Boberg KM，Chapman RW，et al. EASL Clinical Practice Guidelines：management of cholestatic liver diseases. J Hepatol，2009，51（2）：237-267.
[9] Cash W J， O'Neill S，O'Donnell ME，et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int，2013，33（8）：1166-1174.
[10] Stojakovic T，Putz-Bankuti C，Fauler G，et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology，2007，46（3）： 776-784.
[11] Leuschner M， Holtmeier J，Ackermann H，et al. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid：a pilot study. Eur J Gastroenterol Hepatol，2002，14（12）：1369-1376.
[12] Silveira MG，Lindor KD. Treatment of primary biliary cirrhosis： therapy with choleretic and immunosuppressive agents. Clin Liver Dis，2008，12（2）：425-443.
[13] Rabahi N，Chrétien Y，Gaouar F，et al. Triple therapy with ursodeoxycholic acid，budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol，2010，34（4-5）：283-287.
[14] Angulo P，Jorgensen RA，Keach JC，et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology，2000，31（2）：318-323.
[15] Silveira MG，Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother，2014，15（3）：365-372.
[16] Kaplan MM，Bonder A，Ruthazer R，et al. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci，2010，55（11）：3207-3217.
[17] Giljaca V，Poropat G，Stimac D，et al. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev，2010，12（5）： CD004385
[18] Poupon R. Evidence-based treatment of primary biliary cirrhosis. Dig Dis，2014，32（5）：626-630.
[19] Al-Harthy N，Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med，2012，4：61-71.
[20] Gong Y，Christensen E，Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev，2007，（3）：CD006000.
[21] Gong Y，Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev，2004，（2）：CD004481.
[22] Leung J，Bonis PA，Kaplan MM. Colchicine or methotrexate， with ursodiol，are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol，2011，9（9）：776-80.
[23] Angulo P，Patel T，Jorgensen RA，et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology，2000，32（5）： 897-900.
[24] Pares A. Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis，2014，34（3）：341-351.
[25] Bergasa NV，Alling DW，Talbot TL，et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis：a controlled study. J Am Acad Dermatol，1999，41（3Pt1）： 431-434.
[26] Bergasa NV，Talbot TL，Alling DW，et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology，1992，102（2）：544-549.
[27] Parés A，Guanabens N. Osteoporosis in primary biliary cirrhosis：pathogenesis and treatment. Clin Liver Dis，2008，12：407-424.
[28] Dempster DW，Lambing CL，Kostenuik PJ，et al. Role of RANK ligand and denosumab，a targeted RANK ligand inhibitor，in bone health and osteoporosis：a review of preclinical and clinical data. Clin Ther，2012，34：521-536.
[29] Hazzan R， Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol，2010，44（5）：371-373.
[30] Levy C，Peter JA，Nelson DR，et al. Pilot study： fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther，2011，33（2）：235-242.
[31] Talwalkar JA，Lindor kD. Primary biliary cirrhosis. Lancet， 2003，362：53-61.
[32] Kaplan MM，Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med，2005，143：546-547.
[33] Mason AL， Lindor KD，Bacon BR，et al. Clinical trial： Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther，2008，28（7）：886-894.
[34] Charatcharoenwitthaya P，Talwalkar J A，Angulo P，et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci， 2010，55（2）：476-483.